血管紧张素Ⅱ受体拮抗剂联合阿司匹林治疗老年慢性肾脏病的疗效及安全性分析OA
Efficacy and safety analysis of angiotensinⅡ receptor blocker combined with aspirin in elderly patients with chronic kidney disease
目的 探讨血管紧张素Ⅱ受体拮抗剂(ARB)联合阿司匹林治疗老年慢性肾脏病(CKD)患者的疗效与安全性.方法 回顾性选取 2020 年 9 月—2023 年 9 月空军军医大学第一附属医院老年病科收治的130 例老年 CKD 患者作为研究对象,根据患者服用 ARB 类药物时是否联用阿司匹林,将患者分为对照组及观察组,对照组为单独使用 ARB,观察组为 ARB 与阿司匹林联用,每组各65 例.观察治疗后1 年指标的变化,比较治疗前后肾功能指标[估算肾小球滤过率(eGFR)、胱抑素 C],并对轻、中度与重度肾功能不全患者的 eGFR 水平进行亚组分析,比较治疗前后肝功能指标(丙氨酸氨基转移酶)、凝血功能指标(活化部分凝血活酶时间、血小板计数)及不良反应.结果 两组治疗后 eGFR 均升高、胱抑素 C 均降 低,观察组治疗后 eGFR 高于对照组、胱抑素 C 低于对照组,差异均有统计学意义(P<0.05);两组轻、中度肾功能不全亚组患者治疗后 eGFR 较治疗前上升,差异具有统计学意义(P<0.05),两组重度肾功能不全亚组患者治疗前后 eGFR 差异均无统计学意义(P>0.05);两组治疗前后及组间肝功能指标、凝血功能指标比较,差异均无统计学意义(P>0.05).观察组 6 例发生不良反应(包括牙龈出血、大便隐血、消化道不适),均可防可控.结论 轻、中度老年 CKD 患者在 ARB 基础上联用阿司匹林可改善肾功能且无严重不良反应,重度老年 CKD 患者未显示进一步获益.这为临床医生制定老年 CKD 患者联合用药方案时,提供了分层管理的循证依据,有助于实现个体化精准用药决策.
Objective To investigate the efficacy and safety of angiotensin Ⅱ receptor blocker(ARB)combined with aspi-rin in elderly patients with chronic kidney disease(CKD).Methods A retrospective study was conducted on 130 elderly CKD pa-tients admitted to the department of geriatrics,First Affiliated Hospital of Air Force Medical University from September 2020 to Septem-ber 2023.Based on whether aspirin was used in combination with ARBs,patients were divided into a control group(ARB alone)and an observation group(ARB combined with aspirin),with 65 cases in each group.Changes in indicators were observed after one year of treatment.Renal function indicators[estimated glomerular filtration rate(eGFR),cystatin C]were compared before and after treat-ment.Subgroup analysis of eGFR levels was performed for patients with mild-to-moderate and severe renal impairment.Liver function indicators(alanine aminotransferase),coagulation function indicators(activated partial thromboplastin time,platelet count),and ad-verse reactions were also compared.Results After treatment,eGFR increased and cystatin C decreased in both groups.The observa-tion group had significantly higher eGFR and lower cystatin C than the control group(P<0.05).In the mild-to-moderate renal impair-ment subgroups,eGFR significantly increased after treatment in both groups(P<0.05),while no significant changes in eGFR were observed in the severe renal impairment subgroups(P>0.05).There were no statistically significant differences in liver function or co-agulation function indicators between or within groups before and after treatment(P>0.05).Six patients in the observation group expe-rienced adverse reactions(including gingival bleeding,fecal occult blood,and gastrointestinal discomfort),all of which were preventa-ble and controllable.Conclusion For elderly CKD patients with mild-to-moderate renal impairment,adding aspirin to ARB therapy can improve renal function without serious adverse effects.No further benefit was observed in elderly patients with severe CKD.These findings provide evidence for stratified management when clinicians formulate combination medication regimens for elderly CKD pa-tients,helping to achieve individualized and precise drug decisions.
贾旭钊;邓玉洁;王凯曼;刘艳
空军军医大学第一附属医院老年病科,陕西 西安 710032空军军医大学第一附属医院老年病科,陕西 西安 710032空军军医大学第一附属医院老年病科,陕西 西安 710032空军军医大学第一附属医院老年病科,陕西 西安 710032
血管紧张素Ⅱ受体拮抗剂阿司匹林慢性肾脏病疗效安全性
Angiotensin Ⅱ receptor blockerAspirinChronic kidney diseaseEfficacySafety
《国际老年医学杂志》 2026 (5)
590-594,5
国家自然科学基金(82300370)
评论